The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Novel agents in MZL: BTKis, PI3K inhibitors, and immunotherapeutics
Izidore Lossos, MD, University of Miami, Miami, FL, explores the use of new agents for the treatment of marginal zone lymphoma (MZL), including BTK inhibitors (BTKis), phosphoinositide 3-kinase inhibitors (PI3K inhibitors), and CAR-T therapies. Such therapies have shown promise in clinical trials; however, each treatment also has limitations. Dr Lossos also mentions the lack of data collected for other novel agents, such as bispecifics and antibody-drug conjugates, emphasizing how future studies should focus on the MZL cohort. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
